Compass Pathways stock jumped Wednesday after the psychedelics-tied biotech significantly boosted its cash holdings.

Shares of Compass Pathways (NASDAQ:CMPS) climbed nearly 8% in premarket trading on Wednesday after the company reported first ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results ...

Compass Pathways PLC (CMPS) reports positive Phase III results for COMP360, while navigating regulatory and competitive challenges.

Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Compass Pathways may be the first to benefit from an accelerated approval process.

Good day ladies and gentlemen and welcome to The Compass Pathways 1st Quarter Results Conference call. At this time, all participants are in listen only mode. As a reminder, this call is being ...

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards ...

A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...

FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating momentum 26-week (Part B) data from COMP006, ...